This multi-faceted approach makes them effective for weight loss, though the magnitude varies by medication and dose
Cal LA, Davis PA, Pagnin E, et al
For example, there are concerns about the use of exogenous ESAs, which can lead to more death and heart problems in patients who do not respond well or who have cancer
The evidence base is preclinical for IGF-1 LR3 specifically, with adjacent human data from native rhIGF-1 (mecasermin/Increlex)
First, SFN stands as a exemplary multi-targeted agent whose pleiotropic mechanismsspanning epigenetic regulation, induction of specialized cell death programs, immunomodulation, and CSC targetingprovide a robust foundation for its efficacy against heterogeneous and treatment-resistant malignancies
Realistic expectations are 0.25-0.5 kg (0.5-1 lb) per week under optimal conditions, with the rate influenced by baseline body composition, dietary habits, activity level, and individual metabolic responsiveness